Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
NOVOLOG MIX 50/50 is a premixed insulin combining 50% insulin aspart (rapid-acting) and 50% insulin aspart protamine (intermediate-acting) for subcutaneous injection. It is indicated for type 1 and type 2 diabetes management in patients requiring both rapid and basal insulin coverage. This biphasic formulation provides convenient once or twice-daily dosing by combining two insulin components in a single injectable.
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating defensive positioning and potential resource reallocation toward pipeline assets.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NOVOLOG MIX 50/50 offers experience in a mature, LOE-approaching insulin category with established market dynamics and stable patient populations. Career progression here emphasizes defensive brand strategy, market segmentation, and managed care negotiation rather than launch innovation.
Worked on NOVOLOG MIX 50/50 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.